KRAS and neoplasm: Thus, in the adagrasib resistant SW1573 model harboring KRAS-G12C and CDKN2A homozygous loss, adagrasib and abemaciclib combination, but not adagrasib alone, mediated anti-tumor effects and survival prolongation.